The entities presented their findings at ACG 2019, Oct. 25-30 in San Antonio. The study attempted to find biomarkers that would increase the specificity of Exact’s Cologuard, while maintaining its sensitivity.
Researchers tested the new markers alongside Cologuard’s existing markers on 725 stool samples, of which 117 had CRC, 120 had advanced adenomas, 161 had non-advanced adenomas and 327 were controls.
The new markers touted 92 percent sensitivity for CRC and 65 percent sensitivity for advanced adenomas at a 92 percent specificity, surpassing the performance of Cologuard’s current markers.
To build on these results, Exact launched a 10,000-patient, multicenter study which will examine how the markers perform in a real-word setting.
“While further studies will establish the clinical performance of these new markers, we are encouraged by the strong results presented today,” said Paul Limburg, MD, Exact’s CMO.
More articles on surgery centers:
Meet the 11 GIs featured in October
The rise of Gastro Health — A timeline
Dr. Shruti Sevak joins Michigan medical center — 3 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.